Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

PURPOSE OF REVIEW: Psoriatic arthritis (PsA) is an inflammatory arthritis causing significant joint damage and impaired quality of life. A treat to target approach has revolutionized the care of patients with rheumatoid arthritis over the last decade. There is now increasing interest in a similar approach in PsA, as it seems that ongoing joint inflammation predicts subsequent damage and loss of function. RECENT FINDINGS: A 2011 European League Against Rheumatism review highlighted a lack of evidence for treat to target in PsA. However, with the development of the minimal disease activity criteria, a target is available and preliminary results from the first randomized treat-to target study (Tight Control of PsA Study) using these criteria have shown significant benefit in joint and skin disease activity and patient-reported outcomes. SUMMARY: Early evidence has shown the potential benefit of a treat-to-target approach in PsA and further research is needed to optimize treatment pathways for all subtypes of the disease.

Original publication

DOI

10.1097/BOR.0000000000000140

Type

Journal article

Journal

Curr opin rheumatol

Publication Date

03/2015

Volume

27

Pages

107 - 110

Keywords

Anti-Inflammatory Agents, Non-Steroidal, Antirheumatic Agents, Arthritis, Psoriatic, Humans, Outcome Assessment (Health Care), Severity of Illness Index